HRP20010259B1 - Stable liquid formulations of botulinum toxin - Google Patents

Stable liquid formulations of botulinum toxin

Info

Publication number
HRP20010259B1
HRP20010259B1 HR20010259A HRP20010259A HRP20010259B1 HR P20010259 B1 HRP20010259 B1 HR P20010259B1 HR 20010259 A HR20010259 A HR 20010259A HR P20010259 A HRP20010259 A HR P20010259A HR P20010259 B1 HRP20010259 B1 HR P20010259B1
Authority
HR
Croatia
Prior art keywords
botulinum toxin
stable liquid
liquid formulations
stable
composition
Prior art date
Application number
HR20010259A
Other languages
English (en)
Croatian (hr)
Inventor
Moyer Elizabeth
Hirtzer Pamela
Original Assignee
Elan Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22277018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20010259(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharmaceuticals filed Critical Elan Pharmaceuticals
Publication of HRP20010259A2 publication Critical patent/HRP20010259A2/hr
Publication of HRP20010259B1 publication Critical patent/HRP20010259B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
HR20010259A 1998-09-11 2001-04-09 Stable liquid formulations of botulinum toxin HRP20010259B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9987098P 1998-09-11 1998-09-11
PCT/US1999/020912 WO2000015245A2 (en) 1998-09-11 1999-09-09 Stable liquid formulations of botulinum toxin

Publications (2)

Publication Number Publication Date
HRP20010259A2 HRP20010259A2 (en) 2005-02-28
HRP20010259B1 true HRP20010259B1 (en) 2007-11-30

Family

ID=22277018

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010259A HRP20010259B1 (en) 1998-09-11 2001-04-09 Stable liquid formulations of botulinum toxin

Country Status (41)

Country Link
US (2) US7211261B1 (de)
EP (1) EP1112082B2 (de)
JP (4) JP4557426B2 (de)
KR (1) KR100699756B1 (de)
CN (1) CN100438905C (de)
AP (1) AP1591A (de)
AR (1) AR022671A1 (de)
AT (1) ATE221386T1 (de)
AU (1) AU755556C (de)
BG (1) BG65555B1 (de)
BR (1) BR9913585A (de)
CA (1) CA2342243C (de)
CO (1) CO5170497A1 (de)
CU (1) CU23251A3 (de)
DE (1) DE69902396T3 (de)
DK (1) DK1112082T4 (de)
EA (1) EA003367B1 (de)
EE (1) EE200100140A (de)
ES (1) ES2181473T5 (de)
GE (1) GEP20032946B (de)
HK (1) HK1040927A1 (de)
HR (1) HRP20010259B1 (de)
HU (1) HUP0103638A3 (de)
ID (1) ID28824A (de)
IL (2) IL141564A0 (de)
IS (1) IS2381B (de)
LT (1) LT4959B (de)
LV (1) LV12684B (de)
NO (1) NO328898B1 (de)
NZ (1) NZ509349A (de)
PL (1) PL200926B1 (de)
PT (1) PT1112082E (de)
RS (1) RS50344B (de)
SA (1) SA99200566B1 (de)
SI (2) SI20566B (de)
SK (1) SK286919B6 (de)
TR (1) TR200100728T2 (de)
TW (1) TW574036B (de)
UA (1) UA72477C2 (de)
WO (1) WO2000015245A2 (de)
ZA (1) ZA200101709B (de)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312047A1 (en) * 1994-05-09 1995-11-16 William J. Binder Method for reduction of headache pain
US20120238504A1 (en) * 1998-09-11 2012-09-20 Solstice Neurosciences, Llc Stable Formulations of Botulinum Toxin in Hydrogels
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US7838007B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
DK1253932T3 (da) * 2000-02-08 2005-06-27 Allergan Inc Lægemidler med botulinustoxin
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6821520B2 (en) 2000-02-15 2004-11-23 Allergan, Inc. Clostridial toxin therapy for Hashimoto's thyroiditis
ITUD20010002A1 (it) * 2001-01-05 2002-07-05 Univ Degli Studi Udine Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo
CA2369810C (en) * 2002-01-30 2007-08-07 1474791 Ontario Limited Method of treating pain
US6688311B2 (en) 2002-03-14 2004-02-10 Allergan, Inc. Method for determining effect of a clostridial toxin upon a muscle
US7140371B2 (en) 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
AU2003221050A1 (en) * 2002-03-29 2003-10-13 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Remedy for hypermyotonia
US7691394B2 (en) 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
EP1565210B1 (de) 2002-11-21 2012-01-11 Ira Sanders Clostridien-Neurotoxin zur Verwendung in der Behandlung der Verstopfung der Nase
NZ540425A (en) * 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
EP1599220B1 (de) * 2003-03-06 2013-07-17 Botulinum Toxin Research Associates, Inc. Auswahl von patienten mit erhöhtem ansprechen auf botulinustoxin
US8691769B2 (en) * 2003-03-06 2014-04-08 Botulinum Toxin Research Associates, Inc. Treatment of sinusitis related chronic facial pain and headache with botulinum toxin injections
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
JP2007527431A (ja) 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
SG150568A1 (en) * 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
KR100852822B1 (ko) 2004-07-26 2008-08-18 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 신경독소를 포함하는 치료 조성물
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7179474B2 (en) 2004-09-03 2007-02-20 Allergan, Inc. Methods for treating a buttock deformity
WO2006073410A1 (en) * 2005-01-03 2006-07-13 Botulinum Toxin Research Associates, Inc. Compositions, methods and devices for preparing less painful botulinum toxin formulations
CA2599017C (en) 2005-03-03 2014-08-12 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US7419675B2 (en) 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
DE102006019447A1 (de) * 2006-04-24 2007-10-25 Dressler, Dirk, Dr. Markierung von Botulinum Toxin
AR061669A1 (es) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP2048156A1 (de) * 2007-10-12 2009-04-15 Merz Pharma GmbH & Co.KGaA Prozess zur Bereitstellung eines temperaturstabilen Muskelrelaxans auf der Basis der neurotoxischen Komponente von Botulintoxin
WO2008145359A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20170361130A9 (en) * 2008-05-23 2017-12-21 Pankaj Modi Stabilized and solubilized drug formulation for topical application and transdermal efficacy for cosmetic improvement and methods of formulation
EP2315598A1 (de) * 2008-08-05 2011-05-04 Solstice Neurosciences, Inc. Zusammensetzungen aus aktiviertem botulintoxin vom typ b
WO2010016901A1 (en) * 2008-08-05 2010-02-11 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
WO2010051038A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum holotoxin type b (150 kd)
WO2010051039A1 (en) * 2008-11-03 2010-05-06 Solstice Neurosciences, Inc. Compositions of activated botulinum toxin type b
US20100124559A1 (en) * 2008-11-20 2010-05-20 Allergan, Inc. Early Treatment and Prevention of Increased Muscle Tonicity
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
SG10202100698QA (en) 2008-12-31 2021-02-25 Revance Therapeutics Inc Injectable Botulinum Toxin Formulations
EP2248518B1 (de) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulierung zur Stabilisierung von Proteinen, Peptiden und deren Mischungen.
US9340587B2 (en) 2009-06-25 2016-05-17 Revance Therapeutics, Inc. Albumin-free botulinum toxin formulations
CN102471765B9 (zh) 2009-07-02 2016-07-27 莫茨制药有限及两合公司 显示出缩短的生物学活性的神经毒素
ES2688065T3 (es) * 2009-10-21 2018-10-30 Revance Therapeutics, Inc. Métodos y sistemas para purificar la neurotoxina botulínica no complejada
EP2667859A2 (de) * 2011-01-24 2013-12-04 Anterios, Inc. Nanopartikelzusammensetzungen, formulierungen daraus und verwendung
ES2638333T3 (es) 2011-11-09 2017-10-19 Merz Pharma Gmbh & Co. Kgaa Neurotoxinas que presentan una actividad biológica reducida
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
DK3188706T3 (da) * 2014-09-02 2020-01-20 American Silver Llc Botulinumtoksin og kolloide sølvpartikler
CA2971238C (en) 2014-12-23 2022-12-13 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
EP3253364A1 (de) * 2015-02-03 2017-12-13 Merz Pharma GmbH & Co. KGaA Mit botulinumtoxin vorgefüllter behälter
SG11201810561YA (en) * 2016-05-27 2018-12-28 Nestle Skin Health Sa Liquid neurotoxin formulation stabilized with tryptophan or tyrosine
WO2018038301A1 (en) * 2016-08-26 2018-03-01 Hugel Inc. Stabilized liquid formulation of botulinum toxin and preparation method thereof
JP2019526611A (ja) 2016-09-13 2019-09-19 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 非タンパク質クロストリジウム毒素組成物
KR102487144B1 (ko) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 큰 물질의 경피 전달
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물
US20200179498A1 (en) * 2017-05-18 2020-06-11 Revance Therapeutics, Inc. Methods of treatment for cervical dystonia
KR102063475B1 (ko) 2018-02-22 2020-01-09 주식회사 에이비바이오 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법
WO2020074419A1 (en) 2018-10-08 2020-04-16 Merz Pharma Gmbh & Co. Kgaa Neurotoxin prefilled vial

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3522247A (en) * 1967-11-07 1970-07-28 Pfizer & Co C 2-amino-6,7-disubstituted-4h-1,3-benzothiazine-4-ones as bronchodilators
US4932936A (en) 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
CA2138020C (en) 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
JPH06192118A (ja) * 1992-09-28 1994-07-12 Wisconsin Alumni Res Found ボツリヌス毒素を含む異常に過敏な筋運動障害の治療用薬剤組成物およびその製造方法
WO1994028923A1 (en) 1993-06-10 1994-12-22 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
ES2168302T3 (es) 1993-06-10 2002-06-16 Allergan Inc Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
GB9315306D0 (en) 1993-07-23 1993-09-08 Smithkline Beecham Corp Methods
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
EP1563843B1 (de) 1993-12-28 2013-08-07 Allergan, Inc. Botulinustoxin zur Behandlung von Muskelkrankheiten
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CA2312047A1 (en) 1994-05-09 1995-11-16 William J. Binder Method for reduction of headache pain
AU2907695A (en) * 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5512547A (en) 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
US5562899A (en) 1995-02-28 1996-10-08 Gerber; Allen Medical prevention of lacerations to the vagina and perineum
US6136551A (en) * 1995-04-24 2000-10-24 Allergan, Inc. Assay for detecting the presence of botulinum toxin neutralizing antibodies in a patient serum sample
EP0773788B1 (de) 1995-06-06 2003-05-07 L. Bruce Pearce Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6699966B1 (en) * 1996-07-08 2004-03-02 University Of Massachusetts Proteins within the type E botulinum neurotoxin complex
CN1057430C (zh) * 1996-10-09 2000-10-18 崔生发 一种生物化学杀鼠剂
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DK1253932T3 (da) * 2000-02-08 2005-06-27 Allergan Inc Lægemidler med botulinustoxin
US6358513B1 (en) 2000-02-15 2002-03-19 Allergan Sales, Inc. Method for treating Hashimoto's thyroiditis
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US20080096238A1 (en) * 2004-03-30 2008-04-24 Alcon, Inc. High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio
ES2509872T3 (es) * 2005-03-03 2014-10-20 Allergan, Inc. Procedimientos para obtener una toxina clostrídica
CA2601577A1 (en) 2005-03-15 2006-09-21 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
US7855268B2 (en) * 2006-06-01 2010-12-21 Allergan, Inc. Tolerogizing compositions comprising botulinum toxin type B peptides

Also Published As

Publication number Publication date
TR200100728T2 (tr) 2001-08-21
KR20010086388A (ko) 2001-09-10
NZ509349A (en) 2003-08-29
NO20011207D0 (no) 2001-03-09
DE69902396T2 (de) 2003-03-20
EE200100140A (et) 2002-06-17
KR100699756B1 (ko) 2007-03-27
EA200100337A1 (ru) 2001-10-22
SA99200566B1 (ar) 2006-09-20
JP2007169301A (ja) 2007-07-05
SI20566A (sl) 2001-12-31
IL141564A0 (en) 2002-03-10
JP5270594B2 (ja) 2013-08-21
ID28824A (id) 2001-07-05
AP2001002108A0 (en) 2001-03-31
CO5170497A1 (es) 2002-06-27
US7211261B1 (en) 2007-05-01
SI20566B (sl) 2008-08-31
BR9913585A (pt) 2001-06-05
ATE221386T1 (de) 2002-08-15
EP1112082B1 (de) 2002-07-31
UA72477C2 (uk) 2005-03-15
IL141564A (en) 2009-08-03
EA003367B1 (ru) 2003-04-24
ZA200101709B (en) 2002-11-28
IS2381B (is) 2008-07-15
HUP0103638A3 (en) 2004-06-28
LV12684B (lv) 2001-10-20
AU755556C (en) 2005-12-15
IS5836A (is) 2001-01-31
AU755556B2 (en) 2002-12-12
CN100438905C (zh) 2008-12-03
US8173138B2 (en) 2012-05-08
JP2002524527A (ja) 2002-08-06
PT1112082E (pt) 2002-12-31
LV12684A (en) 2001-07-20
DE69902396D1 (de) 2002-09-05
EP1112082A2 (de) 2001-07-04
NO20011207L (no) 2001-05-09
EP1112082B2 (de) 2010-03-17
HK1040927A1 (en) 2002-06-28
JP2010138186A (ja) 2010-06-24
AP1591A (en) 2006-03-20
AU5821499A (en) 2000-04-03
SK286919B6 (sk) 2009-07-06
LT4959B (lt) 2002-10-25
WO2000015245A3 (en) 2000-06-08
BG65555B1 (bg) 2008-12-30
WO2000015245A2 (en) 2000-03-23
SI1112082T1 (en) 2002-12-31
YU19001A (sh) 2005-06-10
AR022671A1 (es) 2002-09-04
HUP0103638A2 (hu) 2002-01-28
CN1316906A (zh) 2001-10-10
JP4557426B2 (ja) 2010-10-06
CA2342243A1 (en) 2000-03-23
GEP20032946B (en) 2003-04-25
PL200926B1 (pl) 2009-02-27
HRP20010259A2 (en) 2005-02-28
PL347069A1 (en) 2002-03-11
ES2181473T5 (es) 2010-07-05
JP2013144691A (ja) 2013-07-25
DK1112082T3 (da) 2002-11-25
US20070148189A1 (en) 2007-06-28
TW574036B (en) 2004-02-01
RS50344B (sr) 2009-11-10
DK1112082T4 (da) 2010-05-31
DE69902396T3 (de) 2010-09-30
NO328898B1 (no) 2010-06-07
CU23251A3 (es) 2007-12-17
SK3132001A3 (en) 2001-10-08
BG105435A (en) 2001-12-29
ES2181473T3 (es) 2003-02-16
LT2001041A (en) 2002-06-25
CA2342243C (en) 2014-01-14

Similar Documents

Publication Publication Date Title
HRP20010259B1 (en) Stable liquid formulations of botulinum toxin
HRP20020880B1 (en) New pharmaceutical composition
RS49721B (sr) Kompozicija koja sadrži biljku i površinski aktivno sredstvo korisna u proizvodnji proizvoda za tretiranje herpesa i drugih mikrobnih infekcija
MEP39108A (en) Pharmaceutical composition
ATE210453T1 (de) Arzneimittel enthaltend botulinum toxin oder neurotoxin und herstellungsverfahren
PT100963A (pt) Composicoes farmaceuticas para aplicacao topica de elevada penetracao atraves da pele que compreendem certos polimeros nao-ionicos especificos
ATE269054T1 (de) Konfekt zusammensetzungen
NO971192D0 (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
ES2144019T3 (es) Composicion farmaceutica que contiene inhibidores de glucosidasa y/o de amilasa, y un inhibidor de lipasa.
PT689438E (pt) Composicoes farmaceuticas para administracao intranasal de apomorfina
PT881901E (pt) Novas associacoes de principios activos contendo clopidogrel e um agente anti-trombotico
ES2098672T3 (es) Composiciones farmaceuticas estabilizadas que contienen derivados de vitaminas d2 y d3.
BR0112417A (pt) Composições farmacêuticas contendo composto dds
DE3583916D1 (de) Waessrige arzneiformulierungen des piroxicammonohydrats.
AR004168A1 (es) Composicion farmaceutica liquida vertible acuosa
SE9702680D0 (sv) New formulation
ES2192704T3 (es) Innovadoras composiciones farmaceuticas.
ME00083B (me) Farmaceutski oblik dronedarona za parenteralnu upotrebu
BR9611642A (pt) Compostos composição farmacéutica e processo para a preparação de compostos
KR910005876A (ko) 모세혈관 취약증의 치료를 위한 극소용 약학적 조성물
PT1178787E (pt) Composicoes farmacologicas para administracao por via oral de floroglucinol e suas preparacoes
DK0506769T3 (da) Farmaceutisk præparat til behandling eller forebyggelse af retrovirus-infektioner
DZ1965A1 (fr) Composition pharmaceutique nouvelle.
BR0001144B1 (pt) Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase
BR0110669A (pt) Composição oral.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: SOLSTICE NEUROSCIENCE, INC., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20100826

Year of fee payment: 12

PBON Lapse due to non-payment of renewal fee

Effective date: 20110910